Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive and functional impairment and behavioural and psychological symptoms (BPSD). As the disease progresses, the patient becomes more functionally impaired with total dependence on caregivers being a hallmark of the more severe stages. The Canadian Study of Health and Aging (CSHA) estimated that 50% of individuals diagnosed with AD were already in the moderate to severe stages, while almost 90% of patients in long-term care facilities were moderate to severe. 1 As dependence on the caregiver increases, the degree of caregiver burden and stress increases, leading to an increased risk of institutionalization for the patient and increased medical and psychological morbidity for the caregiver. 2 Furthermore, the dependence leads to an increased demand on caregiver time, a major contributor to indirect care costs, while institutionalization comprises the most significant ABSTRACT: Moderate to severe Alzheimer's disease (AD) is characterized by increasing cognitive, functional, and behavioural dysfunction that results in increased caregiver burden and, eventually, complete dependence. Despite its significance as a societal health problem, there are few treatment trials of cognitive enhancers or disease modifying agents for this stage of illness. Studies suggest the cholinesterase inhibitors, especially donepezil, may provide benefit. Several studies provide support for the use of the NMDA receptor antagonist memantine as monotherapy or added to a cholinesterase inhibitor for moderate to severe AD. While there are no published guidelines for the treatment of moderate to severe AD, these studies do provide guidance for recommendations for study design and outcome measures. Such studies are urgently needed.
ORIGINAL ARTICLEdriver of direct costs for dementia care. The CSHA estimated that as a result of these factors, the cost of care for AD patients rises dramatically for mild to moderate to severe illness. 3 The Kungsholmen project noted that the severe stages of dementia account for 70-80% of the total costs. 4 Due to its prevalence, associated disability, contribution to caregiver burden, and stress, https://www.cambridge.org/core/terms. https://doi